The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

Sagar Doshi of Nuvama Professional Clients Group recommends these three stocks today- Oil and Natural Gas Corporation Ltd ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

The Indian economy has seen a sharp slowdown, with real GDP growth falling from 8.2 per cent in FY24 to 6 per cent in the first half of FY25. The report highlights a convergence in real and nominal ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...

TARIL is undertaking an ambitious capacity expansion program, which will not only make the company India’s largest ...

Nuvama maintains a defensive portfolio, overweight in private banks, insurance, and sectors like pharma and cement, while ...

Media companies are likely to report a subdued performance in the upcoming Q3FY25 results, according to a report by Nuvama.